Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TBK1 | Q9UHD2 | 12/20 | 0.47 |
| ▸ | JAK2 | O60674 | 3/20 | 0.47 |
| ▸ | IKBKE | Q14164 | 3/20 | 0.44 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20918759 | 1.00 | TBK1 (0.47) | TBK1JAK2IKBKEGPR119 | |
| SCHEMBL20918740 | 0.91 | AAK1 (0.50) | TBK1JAK2IKBKEGPR119 | |
| SCHEMBL20918515 | 0.91 | AAK1 (0.50) | TBK1JAK2IKBKEGPR119 | |
| SCHEMBL28408117 | 0.91 | GPR119 (0.42) | TBK1JAK2GPR119 | |
| SCHEMBL28408114 | 0.91 | TBK1 (0.40) | TBK1JAK2IKBKEGPR119 | |
| SCHEMBL24904138 | 0.90 | GPR119 (0.43) | TBK1JAK2GPR119 | |
| SCHEMBL24904176 | 0.89 | PIK3CD (0.41) | TBK1JAK2GPR119 | |
| SCHEMBL20934771 | 0.88 | TBK1 (0.40) | TBK1JAK2GPR119 | |
| SCHEMBL20918592 | 0.88 | TBK1 (0.40) | TBK1JAK2GPR119 | |
| SCHEMBL20934875 | 0.87 | TBK1 (0.47) | TBK1JAK2IKBKEGPR119 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | EMD Serono Research and Development Institute, Inc. | 2023-01-19 | — | — | US | disclosed |
| EP-3697772-A1 | PYRIMIDINE TBK/IKK INHIBITOR COMPOUNDS AND USES THEREOF | Merck Patent GmbH (DE) | 2020-08-26 | — | — | EP | disclosed |
| CN-111247135-A | Pyrimidine T-K/I-K-P inhibitor compound and application thereof | 默克专利股份公司 | 2020-06-05 | — | — | CN | disclosed |
| WO-2019079373-A1 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
| WO-2019079373-A1 | PYRIMIDINE TBK/IKKε INHIBITOR COMPOUNDS AND USES THEREOF | MERCK PATENT GMBH (DE) | 2019-04-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230019491-A1 | PYRIMIDINE TBK/IKKe INHIBITOR COMPOUNDS AND USES THEREOF | DTYMK, TBKBP1, NFKBIA | TBK1 4/4885JAK2 1021/4885IKBKE 5/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.